How do I treat and follow my TUNA patients

World Journal of Urology

Volumn 24, Issue 4, 2006, Pages 397-404

  Barmoshe, Sas ^a   Zlotta, Alexandre R ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

BPH; Minimally invasive therapy; Prostate enlargement; Radiofrequency; TUNA; TURP

Indexed keywords

ARTICLE; HUMAN; MALE; METHODOLOGY; POSTOPERATIVE CARE; PROSTATE HYPERTROPHY; TRANSURETHRAL RESECTION;

HUMANS; MALE; POSTOPERATIVE CARE; PROSTATIC HYPERPLASIA; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 33748100081     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-006-0091-1     Document Type: Article

References (34)

1. Aho TF, Gilling PJ (2003) Laser therapy for benign prostatic hyperplasia: A review of recent developments. Curr Opin Urol 13(1):39-44
2. Anderson JT, Nickel JC, Marshall VR, Schulman CC, Boyle P (1997) Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 49:839
3. AUA Practice Guidelines Committee (2003) AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1 diagnosis and treatment recommendations. J Urol 170:530
4. Blute ML, Larson T (2001) Minimally invasive therapies for benign prostatic hyperplasia. Urol Suppl 58:33
5. Boyle P, Gould L, Roehrborn C (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride. A meta-analysis of randomized clinical trials. Urology 48:398-405
6. Boyle P, Robertson C, Lowe F, Roehrborn C (2000) Meta-analysis of clinical trials of Permixon in the treatment of BPH. Urology 55:533-539
7. Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG (2001) Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 58:717-722
8. Bruskewitz R, Issa MM, Roehrborn C et al (1998) A prospective, randomised one-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 159:1588-1594
9. Campo B, Bergamaschi F, Corrada P et al (1997) Transurethral needle ablation (TUNA) of prostate: A clinical and urodynamic evaluation. Urology 49:847-850
10. Campo B, Muto G, Rigatti P et al (1995) TUNA: Clinical reliability of a new procedure for prostatic obstruction treatment. J Urol 153:A1220
11. Harewood LM, Cleeve KL, O'Connell HE et al (1995) Transurethral needle ablation of prostate (TUNA): Clinical results and ultrasound, endoscopic, and histologic findings in pilot study of patients in urinary retention. J Endourol 9:407-412
12. Harewood LM, Cleeve LK, O'Connell HE, Pope AJ, Vaughan MG (1994) Transurethral Needle Ablation of the prostate (TUNA): A pilot study in patients in acute retention. J Endourol 8:A17-389
13. Hill B, Belville W, Bruskewitz R, Issa M, Perez-Marrero R, Roehrborn C, Terris M, Naslund M (2004) Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 171(6 Pt 1):2336-2340
14. Kirby RS, Altwein JE, Bartsch G et al (2003) The efficacy and tolerability of doxazosin and finasteride, alone or in combination, in the treatment of symptomatic benign prostatic hyperplasia. results of the prospective European Doxazosin and combination therapy (PREDICT) trial. Urology 61:119-126
15. Lukacs B, Grange JC, Comet D, McCarthy C (1998) Three year prospective study of 3228 clinical BPH patients treated with alfuzosin in general practice. Prostate Cancer Prostatic Dis 1:276
16. Lukacs B, Leplege A, Thibault P, Jardin A (1996) Prospective study of men with clinical benign prostate hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 48:731
17. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387-2398
18. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387
19. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. (1989) Transurethral prostatectomy: Immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 141:243-247
20. Naslund MJ, Benson RC, Cohen ES, Gutierrez-Aceves J, Issa MM (2000) Transurethral needle ablation (TUNA) for BPH in patients with median lobe enlargement. Report of a prospective multi-centre study. AUA Annual Meeting Clinical Abstracts. Williams & Wilkins/Lippincott, Baltimore/ Philadelphia
21. Naslund MJ, Carlson AM, Williams MJ (2005) A cost comparision of medical management and transurethral needle ablation for the treatment of benign prostatic hyperplasia during 5-year period. J Urol 173:2090-2093
22. Plentka L, Loghem JV, Hahn E et al (1991) Comorbidities and perioperative complications among patients with surgically treated benign prostatic hyperplasia. Urology 38(Suppl 1):43
23. Ragavan N, Philip J, Balasubramanian SP, Desouza J, Marr C, Javle P (2005) A randomized, controlled trial comparing lidocaine periprostatic nerve block, diclofenac suppository and both for transrectal ultrasound guided biopsy of prostate. J Urol 174(2):510-513
24. Ramon J, Lynch TH, Eardley I et al (1997) Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: A collaborative multicentre study. Br J Urol 80:128-134
25. Rasor JS, Zlotta AR, Edwards SD, Schulman CC (1993) Transurethral needle ablation: Gradient mapping and comparision of lesion size in a tissue model and in patients with benign prostatic hyperplasia. Eur Urol 24:411-414
26. Roehrborn C, Boyle P, Nickel J, Hoefner K, Andriole G (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434
27. Schulman CC, Zlotta AR (1995) Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: Early clinical experience. Urology. 45(1):28-33
28. Schulman CC, Zlotta AR (1995) TUNA: A promising new therapy for BPH. Contemp Urol 7(10):59-60, 62, 64
29. Steele GS, Sleep DJ (1997) Transurethral needle ablation of the prostate: A urodynamic based study with 2-year followup. J Urol 158(5):1834-1838
30. Vaughan ED Jr (2003) Medical management of benign prostatic hyperplasia - are two drugs better than one? N Engl J Med 349:2449
31. Zlotta AR, Djavan B (2002) Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: Long-term data. Curr Opin Urol 12:7-14
32. Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC (2003) Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for the treatment of symptomatic benign prostatic hyperplasia: Clinical outcome up to five years from three centers. Eur Urol 44:89-93
33. Zlotta AR, Peny MO, Matos C, Schulman CC (1996) Transurethral needle ablation of the prostate: Clinical experience in patients in urinary acute retention. Br J Urol 77(3):391-397
34. Zlotta AR, Schulman CC (1999) Interstitial maser coagulation for the treatment of benign prostatic hyperplasia using local anaesthesia only. BJU Int 83(3):341-342